Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. 

Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury.

As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage.